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Abstract: In November 2020, Brazil ranked third in the number of cases of coronavirus disease 2019
(COVID-19) and second in the number of deaths due to the disease. We carried out a descriptive study
of deaths, mortality rate, years of potential life lost (YPLL) and excess mortality due to COVID-19,
based on SARS-CoV-2 records in SIVEP-Gripe (Ministry of Health of Brazil) from 16 February 2020,
to 1 January 2021. In this period, there were 98,025 deaths from COVID-19 in Brazil. Men accounted
for 60.5% of the estimated 1.2 million YPLLs. High YPLL averages showed prematurity of deaths.
The population aged 45–64 years (both sexes) represented more than 50% of all YPLLs. Risk factors
were present in 69.5% of deaths, with heart disease, diabetes and obesity representing the most
prevalent comorbidities in both sexes. Indigenous people had the lowest number of deaths and
the highest average YPLL. However, in indigenous people, pregnant women and mothers had an
average YPLL of over 35 years. The excess mortality for Brazil was estimated at 122,914 deaths (9.2%).
The results show that the social impacts of YPLL due to COVID-19 are different depending on gender,
race and risk factors. YPLL and excess mortality can be used to guide the prioritization of health
interventions, such as prioritization of vaccination, lockdowns, or distribution of facial masks for the
most vulnerable populations.
Keywords: COVID-19; years of potential life lost; excess mortality
1. Introduction
In December 2019, cases of a new coronavirus were reported in Wuhan, China [1,2],
called severe acute respiratory syndrome severe coronavirus 2 (SARS-CoV-2) or coronavirus
disease 2019 (COVID-19) [3]. On 22 January 2020, the World Health Organization (WHO)
confirmed person-to-person transmission of disease [4]. On January 31, because of the
spread of COVID-19, the WHO declared a global outbreak and, on March 11, recognized it
as a pandemic [5,6].
The first case in Brazil was registered on 26 January 2020 and a public health emergency
was declared on February 3. In the 11th epidemiological week (EW), more than 100 cases
were reported and, in the 12th EW, more than 1000 cases were reported. Community spread
of COVID-19 was recognized in Brazil on March 20 [7,8]. In the 41st EW, Brazil was ranked
third in cases reported (5,566,049) and second in the number of deaths (160,496) [9].
Since the first cases, COVID-19 has caused a significant number of deaths world-
wide [4] and has been recognized as an important public health challenge because of
human, economic and material losses [3,6]. Acter et al. (2020) explained that the pandemic
is a health, humanitarian and development crisis that is advancing worldwide, causing
deaths, damaging immune systems and weakening economies worldwide [3].
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Hospitalized cases of severe acute respiratory syndrome (SARS) must be reported in
the Epidemiological Surveillance System of Influenza (SIVEP-Gripe). These records identify
cases and deaths related to Influenza A and B, Respiratory Syncytial Virus, Adenovirus and
Parainfluenza 1, 2 and 3. In 2020, SIVEP-Gripe began to include cases of hospitalization
and all deaths from COVID-19. In the 12th EW, it began including the results of RT-PCR
tests in the records. The first recorded death was during the ninth EW [8,10].
The indicator of years of potential life lost between 1 and 70 (YPLL), used in mortality
analyzes, helps in health planning, the identification of priorities and the assessment of
social costs for premature deaths [11], although it does not measure morbidity or disability
from an illness [12]. By expressing the social damage caused by premature death from
COVID-19, this indicator provides an alert to society and supports the formulation of
public policies to combat disease.
Excess mortality refers to the total number of deaths that occur during a period above
what is expected for that period. In a pandemic, the number of deaths tends to rise not
only because of the disease but also because of “collateral damage,” such as deaths from
other health conditions that have not been adequately treated because of the overloaded
health system. Excess mortality is an important social indicator of the social and economic
impacts and consequences of a pandemic [13,14].
The objective of this work was to analyze, in an exploratory way, the impact of
COVID-19 in Brazil by analyzing the data on deaths and potential years of life lost. In
addition, excess mortality in Brazil during the year 2020 is presented as an indicator of
the epidemiological scenario during the pandemic period. The hope is that the results of
this study can contribute to other analyses concerning COVID-19, allowing future analyses
and comparisons of the direct and indirect impacts of the pandemic in Brazil with those of
other countries or territories.
2. Materials and Methods
Descriptive data on deaths with symptom onset dates between EW 8 and 53 of 2020
(from 16 February 2020 to 1 January 2021) were recorded in SIVEP-Gripe and made available
for public use after anonymizing the records [15]. In this study, we calculated death rates,
YPLLs due to COVID-19 in Brazil and excess mortality in 2020.
2.1. SIVEP-Gripe
For notification in SIVEP-Gripe, all cases or deaths from SARS were considered,
regardless of hospitalization, that presented influenza syndrome characterized by at least
two of the following signs and symptoms: fever (even if referred), chills, sore throat,
headache, cough, runny nose, smell disturbance and taste disturbance and those who also
presented with dyspnea/respiratory discomfort, persistent chest pressure, O2 saturation of
less than 95% in room air, or bluish coloration of the lips or face [10].
We used the SIVEP-Gripe database updated on 18 January 2021. Cases in which sex
was ignored and those with ages below 1 year or above 70 years were not included. Three
new variables were created: age groups with five-year intervals (except 1–4 years), YPLL
and comorbidity. Other variables recorded were race/color, to create the category “Black”
(cases registered as black and brown) and the “final classification” of the case, which was
based on the reclassification of cases registered as the final classification “other” but with a
description matching COVID-19 (Figure A1).
Mortality rates for Brazil and its geographic regions, proportional mortality, estimated
YPLL by sex, age group, education, race/color and comorbidity and the YPLL rate by
region and federation were calculated. For the denominator of the rates, we used the
population estimated by IBGE for the year 2020 [16]. Analyses involving risk factors are
presented separately, since each death was recorded with some comorbidity and may
present one or more of these factors.
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2.2. Estimates of Years of Potential Life Lost
The YPLL method, proposed by Romeder and McWhinnie (1977), is the sum of the
number of deaths at each age between 1 and 70 years old, multiplied by the remaining
years of life up to 70 years old, organized into age groups with intervals of 5 years and
as-summing a uniform distribution of deaths in the age groups [12]. We calculated the
YPLL using Equation (1), where ai corresponds to the difference between the upper limit
age considered (n) and the age of occurrence of death and di represents the total number of
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2.2.2. Ratio of Years of Potential Life Lost
The COVID-19 YPLL ratios were calculated by gender and for other causes of death
from respiratory and circulatory diseases and from land transport accidents. For other
causes of death, we selected Brazilian Mortality Information System (SIM) records [17]
that listed the following causes of death, according to the 10th revision of the International
Classification of Diseases (ICD-10): diseases of the respiratory system (J00–J99), diseases
of the circulatory system (I00–I99) and land transport accidents (V01–V89). Data were
recorded by state and age between 1 and 70 years old [18].
2.3. Estimate of Excess Mortality
Excess mortality is defined as the sum of the differences between expected and ob-
served deaths from all causes for each month in a specific year. For this study, we used
the model proposed by Vital Strategies in collaboration with WHO [19]. For the projection
of expected deaths for the year 2020, we used SIM data [17] from the period 2015–2019 to
calculate the monthly historical averages and the lower and upper limits.
Total deaths for the year 2020 were obtained from the Civil Registry Transparency
Portal of the Civil Registry Information Center (CR) [20], as SIM data for the year 2020
were not available. Although the CR presents an under-registration, the correction factors
made available by the Brazilian Institute of Geography and Statistics (IBGE) referred to the
year 2018 [21], so we chose not to apply the correction factor.
From the monthly historical mean and using the standard error, confidence intervals
(CIs) were calculated, with the lower and upper values corresponding percentile 2.5 and
97.5. Excess mortality is the sum of the monthly difference between the expected deaths in
the period (upper limit) and the total number of deaths observed in the same period.
2.4. Data Analysis
The YPLL mean and percentage were stratified by sex, age group, race/color, zone,
risk factor and pregnancy status for women, as were the mortality rate, YPLL average and
YPLL rate by region and states of residence. The analyses were performed with SPSS 19.0
(IBM Corp, Armonk, NY, USA).
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3. Results
3.1. Mortality Rate
Of the deaths, 59,608 (60.8%) were male, 44,134 (45.0%) were black and 33,278 (33.9%)
were white. Regarding education, 11,790 (12.0%) had between 10 and 12 years of schooling
and 10,564 (10.8%) had between 1 and 5 years of schooling. Individuals aged between
60 and 69 years represented 45,467 (46.4%) of deaths, followed by those between 50 and
59 years, who represented 25,344 deaths (25.9%). Among fatalities, 73.0% involved a risk
factor (Table 1).
Table 1. Distribution of SARS deaths due to COVID-19 in Brazil (2020) and proportional description according to sociode-
mographic characteristics.
Characteristics
Female, no. (%) Male, no. (%) Total, no. (%)
X2 Square df p
38,417 (39.2) 59,608 (60.8) 98,025 (100)
Race/color
Black 17,317 (45.1) 26,817 (45.0) 44,134 (45.0)
1.796 4 0.773
White 13,082 (34.1) 20,196 (33.9) 33,278 (33.9)
Yellow 394 (1.0) 616 (1.0) 1010 (1.0)
Indigenous 128 (0.3) 222 (0.4) 350 (0.4)
Ignored 7496 (19.5) 11,757 (19.7) 19,253 (19.6)
Education (years)
No
schooling/Illiterate 1082 (2.8) 1230 (2.1) 2312 (2.4)
206.919 6 0.000
1–5 years 4466 (11.6) 6098 (10.2) 10,564 (10.8)
6–9 years 3304 (8.6) 5126 (8.6) 8430 (8.6)
10–12 years 4288 (11.2) 7502 (12.6) 11,790 (12.0)
>12 years old 1446 (3.8) 2896 (4.9) 4342 (4.4)
Not applicable 44 (0.1) 41 (0.1) 85 (0.1)
Ignored 23,787 (61.9) 36,715 (61.6) 60,502 (61.7)
Age Group
01–04 73 (0.2) 67 (0.1) 140 (0.1)
138.169 14 0.000
05–09 31 (0.1) 59 (0.1) 90 (0.1)
10–14 62 (0.2) 75 (0.1) 137 (0.1)
15–19 182 (0.5) 173 (0.3) 355 (0.4)
20–24 372 (1.0) 384 (0.6) 756 (0.8)
25–29 545 (1.4) 695 (1.2) 1240 (1.3)
30–34 951 (2.5) 1326 (2.2) 2277 (2.3)
35–39 1541 (4.0) 2259 (3.8) 3800 (3.9)
40–44 2140 (5.6) 3415 (5.7) 5555 (5.7)
45–49 2798 (7.3) 4682 (7.9) 7480 (7.6)
50–54 3906 (10.2) 6546 (11.0) 10,452 (10.7)
55–59 5637 (14.7) 9255 (15.5) 14,892 (15.2)
60–64 7975 (20.8) 12,378 (20.8) 20,353 (20.8)
65–69 9975 (26.0) 15,139 (25.4) 25,114 (25.6)
≥70 2229 (5.8) 3155 (5.3) 5384 (5.5)
Risk Factor
No 8969 (23.3) 17,464 (29.3 26,433 (27.0)
420.173 1 0.000Yes 29,448 (76.7) 42,144 (70.7) 71,592 (73.0)
Region of Residence
North 3674 (9.6) 6345 (10.6) 10,019 (10.2)
35.475 4 0.000
Northeast 8901 (23.2) 13310 (22.3) 22211 (22.7)
Midwest 3287 (8.6) 5081 (8.5) 8368 (8.5)
Southeast 18,121 (47.2) 27,882 (46.8) 46,003 (46.9)
South 4434 (11.5) 6990 (11.7) 11,424 (11.7)
Zone
Urban 32,073 (83.5) 49,941 (83.8) 82,014 (83.7)
5.473 3 0.140
Rural 1627 (4.2) 2345 (3.9) 3972 (4.1)
Periurban 152 (0.4) 237 (0.4) 389 (0.4)
Ignored 4565 (11.9) 7085 (11.9) 11,650 (11.9)
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The geographic region of the country with the highest number of recorded deaths
from COVID-19 was the south-east, with 46,003 cases (46.9%), followed by the north-
east, with 22,211 cases (22.7%). Most deaths occurred among urban area residents, with
82,014 deaths (83.7%).
During the period, the COVID-19 mortality rate in Brazil was 46.3 deaths/100,000 in-
habitants (Table A1). The northern region presented a mortality rate of 53.7, followed by the
south-eastern and mid-western regions, with mortality rates of 51.7 and 50.7, respectively.
The north-eastern and southern regions had lower mortality rates (Figure 1).




Figure 1. Fatalities and years of potential life lost due to COVID-19 in Brazil (2020) by region and state of residence. 
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average YPLL was 13.1 years for each COVID-19-related death, with the northern and 
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The states with the greatest number of deaths were São Paulo, Rio de Janeiro and 
Minas Gerais in the south-east and Pernambuco and Ceará in the north-east, accounting 
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3.2. Years of Potential Life Lost
The estimated YPLL was 1,280,839, with the south-east and north-east accounting
for 577,128 and 313,004 YPLLs, respectively (combined accounting for 69.5% of YPLLs).
The average YPLL was 13.1 years for each COVID-19-related death, with the northern and
north-eastern regions averaging over 14 years for each death. In the northern, mid-western
and south-eastern regions, the YPLL was higher than the calculated rate of 604.9 years per
100,000 population in Brazil as a whole (Table A2).
The states with the greatest number of deaths were São Paulo, Rio de Janeiro and
Minas Gerais in the south-east and Pernambuco and Ceará in the north-east, accounting
for 53,478 deaths (54.6%). Of the 27 states, 12 had mortality rates above the national rate.
The five states with the highest rates were Rio de Janeiro (78.7), Amazonas (78.5), Distrito
Federal (68.2), Roraima (61.5) and Sergipe (59.5), as shown in Figure 1.
São Paulo, Rio de Janeiro, Minas Gerais, Pernambuco and Ceará contributed 53.2%
of the total YPLLs over the study period. The mean YPLL for eight states was lower
than the national average. The five states with the highest averages were Amapá (15.6),
Roraima (15.4), Acre (15.3) and Rondônia (14.9), all in the northern region. YPLL rates of 15
states were higher than the national average. Amazonas (1083.3), Rio de Janeiro (1,001.2),
Roraima (944.6), Sergipe (910.1) and the Federal District (890.1) were the states with the
highest YPLL rates (Figure 1).
Regarding race/color, 47.5% of the YPLLs occurred in blacks, remaining above 47%
when examined by gender. Indigenous people had a higher average YPLL (16.8 years). In
indigenous women, this average was 19.2 years per death, 3.7 years more than for males.
Of women’s deaths, 227 occurred in pregnant women, with a total of 8,406 years lost
and an average of 37.0 years. Urban areas represented 83.2% of the estimated YPLLs, while
the highest average YPLL (14.3) was observed for rural residents.
People aged 5–9 and 65–69 years had the lowest (90) and highest (25,114) number of
death records, respectively. Those aged 45–64 years represented 55.5% of the estimated
YPLL, whereas those aged 55–59 years accounted for 15.0% of the total YPLLs. The average
YPLLs per death decreased with age, with a higher mean YPLL among those younger than
9 years (Figure 2).




Figure 2. Deaths and years of potential life lost due to COVID-19 in Brazil (2020) by gender and age group. 
 
Figure 3. Fatalities and years of potential life lost in Brazil (2020) due to COVID-19, by gender, race/color, zone residence 
and risk factor. 
Figure 2. Deaths and years of potential life lost due to COVID-19 in Brazil (2020) by gender and age group.
Of the YPLLs, 889,771 (69.3%) occurred among those who had a risk factor. Women
with risk factors accounted for 74.1% of the YPLLs, with an average of 12.7 years for each
death. Among the deaths with risk factors, chronic cardiovascular disease and diabetes
mellitus represented 365,541 and 335,956 YPLLs, respectively (Figure 3). It should be noted
that a single death record can be associated with more than one risk factor.
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The YPLL ratio between the genders showed that the YPLL was higher for men in all
states, with 15 states showing higher values than the nationwide value (1.541) (Figure 4A).
The ratio of YPLLs due to COVID-19 vs. other respiratory diseases that occurred in 2019
showed that the YPLL was lower for COVID-19 only for the state of Amapá and 10 states
had a higher ratio than that of Brazil overall, which was 1.808 (Figure 4B). Based on the
ratio of fatalities due to COVID-19 vs. terrestrial transport accidents, nine states had a
higher YPLL for accidents than for COVID-19, eight states had lower ratios than the overall
ratio of Brazil (1.376) and 10 had ratios above 1.375 (Figure 4D). In five Brazilian states,
the YPLL ratio of deaths due to COVID-19 vs. other cardiovascular diseases was higher
than 1; in the other states, the ratio was lower than 1, along with the nationwide ratio
(0.609), showing that heart diseases had a higher YPLL in 2019 than COVID-19 in 2020
(Figure 4C). The state of the Amazonas was the largest contributor of COVID-19-related
YPLLs and other causes of mortality, sometimes reaching values nine times higher than
those calculated for the country.
3.3. The Expected and Excess Mortality Rate
Excess mortality in Brazil for the year 2020 was calculated at almost 123,000 deaths
(9.2%). São Paulo and Rio de Janeiro, both in the south-east, had the highest excess mortality.
In other regions where the states of the Amazon (north), Pernambuco (north-east), Distrito
Federal (mid-west) and the Rio Grande do Sul (south). The state of Ceará (north-east)
had the highest percentage (218.4%) of excess mortality, followed by the Federal District
(mid-west), with 43.6% (Table A1). Excess mortalities in São Paulo and Rio de Janeiro
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(south-east) were among the highest percentages, both around 19%. The state of Piauí
(north-east) did not present any excess mortality in the evaluated period (Figure 5).
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less than 1. The Brazil-wide ratio is represented by the vertical line on each chart. The names of the states followed by the 
letters (in parentheses) represent the region of the country in which they are located (n = north, ne = north-east, mw = mid-
west, se = south-east and s = south). 
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The south-east and the south had the highest values of excess mortality, but the
mid-western and south-eastern regions had the highest percentages (13%). In the north,
North-east and south-east, the increase in fatalities began in May and, in the mid-west and
south, the increase began in July (Figure 5).
4. Discussion
During the study period, more than 1.2 million YPLLs were recorded in Brazil. The
YPLLs due to COVID-19 in 2020 was higher than the YPLLs for land transport accidents
in 2013, estimated at 1,309,191.5 years by Andrade and Mello-Jorge (2016); YPLLs due
to COVID-19 were also greater than the 608,059 YPLLs estimated by Bochner and Freire
(2020) due to deaths from poisoning during the period between 2010 and 2015 [22,23].
Transport accidents and intoxications have a greater impact on people aged 20–49 years.
The difference in YPLLs found between these two causes occurred because of the higher
number of deaths due to COVID-19.
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Perea et al. (2018) estimated 1,589,501 YPLLs due to deaths from oral and pharyngeal
cancer from 1979 to 2013, in Brazil. The YPLLs due to COVID-19 corresponded to 80.6% of
the YPLLs for these types of cancer during this 35-year historical period [24].
Race/color disparities in both COVID-19 incidence and mortality have affected the
black population more [25,26]. The differences in deaths and YPLLs between blacks and
whites reveal distinct impacts of COVID-19 on these populations. Baqui et al. (2020)
analyzed hospitalized cases (in SIVEP-Gripe) and reported that deaths among browns
and blacks were higher than in whites, indigenous people and Asians; in the states of
the north and north-east, this difference was more than 40% and, in the other states, the
difference was more than 29% [27]. Pierce et al. (2020) analyzed COVID-19 mortality in
Chicago (USA) and estimated the YPLLs per 100,000 inhabitants at 559 years for the black
population and 312 years for whites [28].
These findings were discussed as a reflection of racial inequalities by Wrigley-Field
(2020), who predicted that the difference in life expectancy between whites and blacks will
be even greater because of the COVID-19 pandemic [29]. Oliveira et al. (2020) pointed out
that racial inequalities and structural racism in Brazil should be considered when assessing
the higher lethality among hospitalized blacks than among whites, although the number of
hospitalized blacks was also higher [30].
The gender differences related to COVID-19 are evidenced by the number of deaths,
total YPLLs and the ratio between the sexes, with predominance in men for all these indica-
tors. In our study, men accounted for 53% more YPLLs than women and Arolas et al. [31]
found a 44% percentage in a study conducted in 81 countries. These authors cited a higher
mean age among women, resulting in fewer YPLLs and a higher number of deaths in
absolute values among men, possibly explaining the disparities between our findings. The
YPLL in indigenous people was lower, but the average number of years lost was higher
than the overall average, with more than 19 years for females, indicating a higher impact
on younger age groups.
However, the literature indicates that deaths in pregnant and postpartum women
result from the evolution of the disease and the presence of comorbidities [32–34]. SIVEP-
Gripe has no records of outcomes in pregnant women, such as abortions, stillbirths, or
vertical transmission of COVID-19, which represent social losses not accounted for in YPLL,
although this is discussed in the literature [35,36]. The YPLL of pregnant and postpartum
women found is due to the fact that most women in Brazil become pregnant between the
ages of 20 and 44 [37].
Abate et al. (2021) conducted a systematic review and found a 48% prevalence
of comorbidities in hospitalized patients, with diabetes mellitus (48%) predominating,
followed by hypertension and cardiovascular diseases (15%) [38]. Among the main risk
factors listed in this study were chronic cardiovascular disease, diabetes mellitus and
obesity, which have also been found in other studies [39–42]. Our findings indicated the
presence of a risk factor in 73% of deaths, but these results can be explained by the fact
that we only examined the number of deaths. The literature has shown a correlation of
obesity and other comorbidities with a higher prevalence of hospitalizations and mortality
in COVID-19 infected patients. However, more specific analyses on the presence of risk
factors could not be performed because of the high number of records for which this
information was either ignored or missing (Table A3) [39,41,43].
Excess mortality is an easy-to-calculate indicator; by using up-to-date data and YPLL
to assess and track the evolution of COVID-19, this indicator helps in understanding how
the disease affects populations and territories. It is important to note that excess mortality
is not only a direct reflection of COVID-19, but is also attributable to deaths not related to
the pandemic because of the overloading of health services and failures in the treatment of
chronic diseases [44].
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5. Conclusions
In 2020, almost one year after the first case of COVID-19 in Brazil, more than one mil-
lion YPLLs were reported, more than half of which were due to deaths in the economically
active population. Premature mortality reduces productivity and increases costs for the
national health care system, including costs of hospitalization and treatment before death
and social security costs due to payments to dependents, raising the economic impact
on society.
YPLL rates allow us to compare the dynamics of COVID-19 in Brazilian states, even
though they have heterogeneous socioeconomic and geographic characteristics. The state
of Amazonas in the northern region of the country and Rio de Janeiro in the southeastern
region had YPLL rates above 1000 years of life lost per 100,000 inhabitants, showing
that the social losses in these states were quite similar, even though the total number of
deaths differed.
The excess mortality identified during the period, although not directly associated
with COVID-19 deaths, shows that mortality increased as the pandemic progressed. The
increase in mortality can also be explained by the overloading of health services and the
difficulties of the health system to restructure itself to face the challenges of a pandemic.
In this scenario, other diseases and illnesses were also affected; they no longer received
proper care and monitoring because of the lack of available outpatient services, hospital
beds and health professionals, as these services were displaced to respond to the pandemic.
The deaths of pregnant or postpartum women not only represent a high social cost
but also leave hidden, unmeasurable social losses, such as possible abortions or stillbirths.
Similarly, COVID-19 deaths among the indigenous population carry a high social burden,
especially for ethnicities with smaller and more vulnerable populations. As such, additional
studies to understand these unmeasurable impacts are needed.
The monitoring of these indicators helps in the planning of health actions that seek to
reduce early mortality, such as the definition of more vulnerable groups that should receive
special attention, including priority groups for vaccination.
This study has limitations regarding the lack of data for some variables, such as
education, race/color and risk factors (Table A4). These percentages may have caused bias
in the results. Since education had the highest percentage of ignored information, it was not
considered for the YPLL evaluations. YPLL rates may have a bias because they used data
from the year 2019 on other causes of mortality because of the absence of this information
for the year 2020. The excess mortality calculations may be underestimated because of the
decision not to use correction factors, as they represent delays in death records for SIM
data. This may also explain the absence of excess mortality in the state of Piauí.
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COVID-19 in Brazil (2020).
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Deaths YPLL Cumulative Excess Mortality
No (%) MortalityRate No (%) Mean
YPLL
Rate Observed Excess (%)
Brazil 211,755,692 98,025 (100) 46.3 1,280,839 (100) 13.1 604.9 1,455,522 122,914 (9.2)
North 18,672,591 10,019 (10.2) 53.7 143,106 (11.2) 14.3 766.4 82,063 4643 (6.0)
Acre 89,4470 353 (3.5) 39.5 5399 (3.8) 15.3 603.6 4748 675 (16.6)
Amapá 86,1773 405 (4.0) 47.0 6309 (4.4) 15.6 732.1 3273 306 (10.3)
Amazonas 4,207,714 3302 (33.0) 78.5 45,581 (31.9) 13.8 1083.3 19,217 2660 (16.1)
Pará 8,690,745 3956 (39.5) 45.5 55,846 (39.0) 14.1 642.6 35,467 1989 (5.9)
Rondônia 1,796,460 1025 (10.2) 57.1 15,323 (10.7) 14.9 853.0 9221 1307 (16.5)
Roraima 631,181 388 (3.9) 61.5 5962 (4.2) 15.4 944.6 3024 423 (16.2)
Tocantins 1,590,248 590 (5.9) 37.1 8686 (6.1) 14.7 546.2 7113 184 (2.7)
North-east 57,374,243 22,211 (22.7) 38.7 313,004 (24.4) 14.1 545.5 349,239 13,933 (4.2)
Alagoas 3,351,543 1418 (6.4) 42.3 20,722 (6.6) 14.6 618.3 20,836 1125 (5.7)
Bahia 14,930,634 4373 (19.7) 29.3 60,803 (19.4) 13.9 407.2 91,997 3434 (3.9)
Ceará 9,187,103 4533 (20.4) 49.3 63,450 (20.3) 14.0 690.6 5567 3819 (218.4)
Maranhão 7,114,598 1698 (7.6) 23.9 23,641 (7.6) 13.9 332.3 29,173 424 (1.5)
Paraíba 4,039,277 1764 (7.9) 43.7 25,516 (8.2) 14.5 631.7 29,718 2274 (8.3)
Pernambuco 9,616,621 4790 (21.6) 49.8 65,114 (20.8) 13.6 677.1 72,729 7318 (11.2)
Piauí 3,281,480 1091 (4.9) 33.2 15,805 (5.0) 14.5 481.6 15,296 0 (0.0)
Rio Grande do
Norte 3,534,165 1165 (5.2) 33.0 16,849 (5.4) 14.5 476.7 19,575 521 (2.7)
Sergipe 2,318,822 1379 (6.2) 59.5 21,104 (6.7) 15.3 910.1 14,245 1170 (9.0)
Mid-west 16,504,303 8368 (8.5) 50.7 111,815 (8.7) 13.4 677.5 100,425 13,935 (16.1)
Distrito
Federal 3,055,149 2084 (24.9) 68.2 27,194 (24.3 13.0 890.1 18,353 5570 (43.6)
Goiás 7,113,540 3635 (43.4) 51.1 48,739 (43.6) 13.4 685.2 43,154 4256 (10.9)
Mato Grosso 3,526,220 1273 (15.2) 36.1 18,853 (16.9) 14.8 534.7 19,999 2773 (16.1)
Mato Grosso
do Sul 2,809,394 1376 (16.4) 49.0 17,029 (15.2) 12.4 606.1 18,919 2303 (13.9)
South-east 89,012,240 46,003 (46.9) 51.7 577,128 (45.1) 12.5 648.4 705,485 91,673 (14.9)
Espírito Santo 4,064,052 1848 (4.0) 45.5 24,432 (4.2) 13.2 601.2 29,286 4865 (19.9)
Minas Gerais 21,292,666 5851 (12.7) 27.5 69,777 (12.1) 11.9 327.7 147,566 9666 (7.0)
Rio de Janeiro 17,366,189 13,667 (29.7) 78.7 173,872 (30.1) 12.7 1.001.2 172,702 28,057 (19.4)
São Paulo 46,289,333 24,637 (53.6) 53.2 309,047 (53.5) 12.5 667.6 355,931 50,027 (16.4)
South 30,192,315 11,424 (11.7) 37.8 135,786 (10.6) 11.9 449.7 21,831 14,761 (208.8)
Paraná 11,516,840 4270 (37.4) 37.1 52,745 (38.8) 12.4 458.0 78,461 4574 (6.2)
Rio Grande do
Sul 11,422,973 4408 (38.6) 38.6 51,106 (37.6) 11.6 447.4 93,694 5260 (5.9)
Santa Catarina 7,252,502 2746 (24.0) 37.9 31,935 (23.5) 11.6 440.3 46,155 4920 (11.9)
Mortality rate/100,000 inhabitants. Mean, YPLLs per death; YPLL, years of potential life lost; YPLL rate, rate of years of potential life
lost/100,000 inhabitants.




Female YPLL Mean Male YPLL Mean Total YPLL Mean
38,417 (39.2) 506073 (39.5) 13.2 59608 (60.8) 774,766 (60.5) 13.0 98,025 (100) 1,280,839(100) 13.1
Pregnant
Yes 227 (0.6) 8406 (1.7) 37.0 227 (0.6) 8406 (1.7) 37.0
No 28,213 (73.4) 378,898 (74.9) 13.4 28,213 (73.4) 378,898 (74.9) 13.4
Not applicable 5695 (14.8) 53,882 (10.6) 9.5 5695 (14.8) 53,882 (10.6) 9.5
Ignored 4282 (11.1) 64,887 (12.8) 15.2 4282 (11.1) 64,887 (12.8) 15.2
Race/color
Black 17,317 (45.1) 241,376 (47.7) 13.9 26,817 (45.0) 366,461 (47.3) 13.7 44,134 (45.0) 607,837 (47.5) 13.8
White 13,082 (34.1) 160,826 (31.8) 12.3 20,196 (33.9) 241,661 (31.2) 12.0 33,278 (33.9) 402,487 (31.4) 12.1
Yellow 394 (1.0) 5351 (1.1) 13.6 616 (1.0) 7608 (1.0) 12.4 1010 (1.0) 12,959 (1.0) 12.8
Indigenous 128 (0.3) 2455 (0.5) 19.2 222 (0.4) 3436 (0.4) 15.5 350 (0.4) 5891 (0.5) 16.8
Ignored 7496 (19.5) 96,065 (19.0) 12.8 11,757 (19.7) 155,600 (20.1) 13.2 19,253 (19.6) 251,665 (19.6) 13.1




Female YPLL Mean Male YPLL Mean Total YPLL Mean
38,417 (39.2) 506073 (39.5) 13.2 59608 (60.8) 774,766 (60.5) 13.0 98,025 (100) 1,280,839(100) 13.1
Zone
Urban 32,073 (83.5) 418,720 (82.7) 13.1 49,941 (83.8) 647,337 (83.6) 13.0 82,014 (83.7) 1,066,057(83.2) 13.0
Rural 1627 (4.2) 24,936 (4.9) 15.3 2345 (3.9) 31711 (4.1) 13.5 3972 (4.1) 56,647 (4.4) 14.3
Periurban 152 (0.4) 2264 (0.4) 14.9 237 (0.4) 3173 (0.4) 13.4 389 (0.4) 5437 (0.4) 14.0
Ignored 4565 (11.9) 60,153 (11.9) 13.2 7085 (11.9) 92,545 (11.9) 13.1 11,650 (11.9) 152,698 (11.9) 13.1
Risk Factor
No 8969 (23.3) 131,060 (25.9) 14.6 17,464 (29.3) 260,008 (33.6) 14.9 26,433 (27.0) 391,068 (30.5) 14.8
Yes 29,448 (76.7) 375,013 (74.1) 12.7 42,144 (70.7) 514,758 (66.4) 12.2 71,592 (73.0) 889,771 (69.5) 12.4




14,665 (38.2) 149,817 (39.9) 10.2 21,280 (35.7) 215,724 (41.9) 10.1 35,945 (36.7) 365,541 (41.1) 10.2
Diabetes mellitus 13,720 (35.7) 145,309 (38.7) 10.6 18,263 (30.6) 190,647 (37.0) 10.4 31,983 (32.6) 335,956 (37.8) 10.5
Obesity 4269 (11.1) 65,466 (17.5) 15.3 4797 (8.0) 80,492 (15.6) 16.8 9066 (9.2) 145,958 (16.4) 16.1
Chronic Kidney
Disease 2571 (6.7) 34,058 (9.1) 13.2 4207 (7.1) 48,457 (9.4) 11.5 6778 (6.9) 82,515 (9.3) 12.2
Immunodeficiency/
Immunodepression 2114 (5.5) 33,997 (9.1) 16.1 2557 (4.3) 40,832 (7.9) 16.0 4671 (4.8) 74,829 (8.4) 16.0
Other Chronic




1357 (3.5) 19,055 (5.1) 14.0 1980 (3.3) 25,504 (5.0) 12.9 3337 (3.4) 44,559 (5.0) 13.4
Asthma 1454 (3.8) 22,147 (5.9) 15.2 989 (1.7) 16,302 (3.2) 16.5 2443 (2.5) 38,449 (4.3) 15.7
Chronic Liver




459 (1.2) 7568 (2.0) 16.5 627 (1.1) 9846 (1.9) 15.7 1086 (1.1) 17,414 (2.0) 16.0
Down Syndrome 218 (0.6) 5207 (1.4) 23.9 229 (0.4) 5162 (1.0) 22.5 447 (0.5) 10,369 (1.2) 23.2
Other 13,624 (35.5) 174,375 (46.5) 12.8 18,554 (31.1) 227,523 (44.2) 12.3 32,178 (32.8) 401,898 (45.2) 12.5
Mean, YPLL per total deaths; YPLL, years of potential life lost.





Female YPLL Mean Male YPLL Mean Total YPLL Mean
38,417 (392) 506,073(39.5) 13.2
59,608
(60.8) 774,766 (60.5) 13.0 98,025 (100)
1,280,839
(100) 13.1
1–4 73 (0.2) 4980 (1.0) 68.2 67 (0.1) 4541 (0.6) 67.8 140 (0.1) 9521 (0.7) 68.0
5–9 31 (0.1) 1952 (0.4) 63.0 59 (0.1) 3743 (0.5) 63.4 90 (0.1) 5695 (0.4) 63.3
10–14 62 (0.2) 3585 (0.7) 57.8 75 (0.1) 4322 (0.6) 57.6 137 (0.1) 7907 (0.6) 57.7
15–19 182 (0.5) 9599 (1.9) 52.7 173 (0.3) 9101 (1.2) 52.6 355 (0.4) 18,700 (1.5) 52.7
20–24 372 (1.0) 17,807 (3.5) 47.9 384 (0.6) 18,330 (2.4) 47.7 756 (0.8) 36,137 (2.8) 47.8
25–29 545 (1.4) 23,361 (4.6) 42.9 695 (1.2) 29,724 (3.8) 42.8 1240 (1.3) 53,085 (4.1) 42.8
30–34 951 (2.5) 35,919 (7.1) 37.8 1326 (2.2) 50,067 (6.5) 37.8 2277 (2.3) 85,986 (6.7) 37.8
35–39 1541 (4.0) 50,557 (10.0) 32.8 2259 (3.8) 74,127 (9.6) 32.8 3800 (3.9) 124,684 (9.7) 32.8
40–44 2140 (5.6) 59,702 (11.8) 27.9 3415 (5.7) 95,154 (12.3) 27.9 5555 (5.7) 154,856 (12.1) 27.9
45–49 2798 (7.3) 63,966 (12.6) 22.9 4682 (7.9) 107,085 (13.8) 22.9 7480 (7.6) 171,051 (13.4) 22.9
50–54 3906 (10.2) 69,770 (13.8) 17.9 6546 (11.0) 116,846 (15.1) 17.8 10,452 (10.7) 186,616 (14.6) 17.9
55–59 5637 (14.7) 72,589 (14.3) 12.9 9255 (15.5) 119,403 (15.4) 12.9 14,892 (15.2) 191,992 (15.0) 12.9
60–64 7975 (20.8) 62,924 (12.4) 7.9 12,378 (20.8) 97,683 (12.6) 7.9 20,353 (20.8) 160,607 (12.5) 7.9
65–69 9975 (26.0) 29,362 (5.8) 2.9 15,139 (25.4) 44,640 (5.8) 2.9 25,114 (25.6) 74,002 (5.8) 2.9
≥70 2229 (5.8) 0 (0.0) 0.0 3155 (5.3) 0 (0.0) 0.0 5384 (5.5) 0 (0.0) 0.0
Mean, YPLL per total deaths; YPLL, years of potential life lost.
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Table A4. Risk factors for gender in Brazil, 2020.
Risk Factor
Female Male






Yes 14,665 38.2 21,280 35.7
No 8371 21.8 12,036 20.2
Missing 15,381 40.0 26,292 44.1
Diabetes mellitus
Yes 13,720 35.7 18,263 30.6
No 8926 23.2 13,954 23.4
Missing 15,771 41.1 27,391 46.0
Obesity
Yes 4269 11.1 4797 8.0
No 13,830 36.0 21,025 35.3
Missing 20,318 52.9 33,786 56.7
Chronic Kidney Disease
Yes 2571 6.7 4207 7.1
No 15,419 40.1 22,149 37.2
Missing 20,427 53.2 33,252 55.8
Immunodeficiency/
Immunodepression
Yes 2114 5.5 2557 4.3
No 15,593 40.6 23,128 38.8
Missing 20,710 53.9 33,923 56.9
Other Chronic Pneumopathy
Yes 1858 4.8 26,65 4.5
No 15,890 41.4 23,214 38.9
Missing 20,669 53.8 33,729 56.6
Chronic Neurological Disease
Yes 1357 3.5 1980 3.3
No 16,174 42.1 23,605 39.6
Missing 20,886 54.4 34,023 57.1
Asthma
Yes 1454 3.8 989 1.7
No 16,094 41.9 24,253 40.7
Missing 20,869 54.3 34366 57.7
Chronic Liver Disease
Yes 524 1.4 1252 2.1
No 16,716 43.5 24,059 40.4
Missing 21,177 55.1 34,297 57.5
Chronic Hematologic Disease
Yes 459 1.2 627 1.1
No 16,807 43.7 24,565 41.2
Missing 21,151 55.1 34,416 57.7
Down Syndrome
Yes 218 0.6 229 0.4
No 17,070 44.4 24,904 41.8
Missing 21,129 55.0 34475 57.8
Other
Yes 13,624 35.5 18,554 31.1
No 8308 21.6 12,446 20.9
Missing 16,485 42.9 28,608 48.0
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